Matthew B.

Matthew B. is a Lead Scientist at Medicines Discovery Catapult since November 2018, with a robust background in drug efficacy studies and predictive toxicology. Prior to this, Matthew worked at AstraZeneca from 2009 to October 2018, focusing on mechanistic biology, cellular efficacy, and the validation of predictive toxicology pathways. Matthew's earlier research at The University of Manchester included positions as a British Heart Foundation Principal Investigator, investigating endothelial signaling in type 2 diabetes, and as a postdoctoral researcher studying endothelial regulation of vascular function. Matthew's academic foundation includes a PhD exploring tyrosine kinase signaling in the cardiovascular system, following a BSc in Physiology earned at University College London.